+0.12 (+4.69%)
Dilution Risk
Revenue
20.27 M
R&D Expenses
3.93 M
Operating CF
8.83 M
Total Assets
37.43 M
Total Liabilities
53.19 M
Equity
-15.75 M
D/E Ratio
12,345
Cash Position
7.28 M
Monthly Burn
-
Runway
12,345 mo
Burn Trend
SEC Filing
May 20, 2026locked
| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
NDA Submission example | crofelemer rare intestinal failure indications | NDA | — | Small Molecules | Rare Diseases | ||
NDA Submission example | crofelemer rare intestinal failure indications | NDA | — | Small Molecules | Rare Diseases | ||
NDA Submission example | crofelemer rare intestinal failure indications | NDA | — | Small Molecules | Rare Diseases |
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Crofelemer Small molecule | Cancer Therapy-Related Diarrhea | Phase 3 | NCT04538625 | 46% | $980M | COMPLETED | 287 | - | - | Oct 30, 2023 | - | Jul 26, 2024 |
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
crofelemer | microvillus inclusion disease (MVID),short bowel syndrome (SBS-IF) | Phase 2 | 2025-06-23 | |||
crofelemer | microvillus inclusion disease (MVID),short bowel syndrome (SBS-IF) | Phase 2 | 2025-06-23 | |||
crofelemer | microvillus inclusion disease (MVID),short bowel syndrome (SBS-IF) | Phase 2 | 2025-06-23 |
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Jaguar Health, Inc. announced the approval of all five proposals at its Annual Meeting of Stockholders held on June 8, 2026. The proposals were previously outlined in the definitive proxy statement filed with the SEC. Additionally, Jaguar's founder, Lisa Conte, is scheduled to present at the Emerging Growth Conference on June 10, 2026. The company specializes in developing plant-derived prescription drugs for gastrointestinal disorders.
Read more →Jaguar Health, Inc. announced that it has regained compliance with Nasdaq's listing rule, allowing its securities to remain traded on the exchange. This comes after reporting an impressive 816% increase in net revenue in Q1 2026 compared to the same period in the previous year. The company is focusing on its development program for an innovative oral formulation of crofelemer, aiming for a new drug application by mid-2027. Jaguar is also looking for a commercialization partner for this project.
Read more →Jaguar Health reported a remarkable 816% increase in net revenue for Q1 2026 compared to Q1 2025, driven by a licensing agreement for Mytesi and Canalevia-CA1. The company is focusing on developing crofelemer for rare intestinal failure diseases, with presentations planned at the upcoming ESPGHAN meeting. Despite the positive revenue growth, prescription product revenue saw a significant decline from the previous quarter.
Read more →Jaguar Health, Inc. has been granted an extension until May 15, 2026, to demonstrate compliance with Nasdaq's $1.00 bid price rule, following a formal notice from the Nasdaq Hearings Panel. To aid this process, the company will execute a reverse stock split at a 1-for-35 ratio, effective April 30, 2026. This split aims to increase the per-share price of its stock and maintain its listing on the Nasdaq Capital Market. The decision to split shares was approved during a Special Meeting of Stockholders.
Read more →Jaguar Health, Inc. announced the successful approval of five proposals at its Special Meeting of Stockholders held on April 20, 2026. The details of these proposals can be found in the definitive proxy statement filed with the SEC. This approval indicates strong support from shareholders for the company's strategic direction.
Read more →Jaguar Health plans to leverage AI platforms to enhance the development and commercialization of crofelemer for intestinal failure, particularly in pediatric patients with microvillus inclusion disease (MVID). The company aims to demonstrate crofelemer's effectiveness and achieve faster FDA approval, addressing a critical unmet medical need. Progress includes a notable reduction in parenteral support in treatment programs and discussions for non-dilutive funding.
Read more →Jaguar Health reported a 5% increase in net revenue for the fourth quarter of 2025 compared to the previous quarter, aided by a $16 million upfront payment from Future Pak for product licensing. The company is shifting its focus towards developing its crofelemer products for rare disease indications. However, it continues to face significant operational losses and challenges related to Nasdaq compliance, which may affect its listing status. An investor webcast has been scheduled for April 10, 2026, to discuss these results and future plans.
Read more →Jaguar Health, Inc. has declared a one-time special stock dividend to its shareholders, consisting of Series O Convertible Preferred Stock. This initiative aims to protect against dilution while the company explores debt restructuring. The Preferred Stock will convert into Common Stock at the Board's discretion, with a planned NDA filing for a rare disease treatment in 2027.
Read more →Jaguar Health has entered into a U.S. licensing agreement with Future Pak, allowing Future Pak to exclusively market Mytesi and Canalevia-CA1. The agreement includes an $18 million upfront payment, with potential future milestone payments totaling up to $20 million. This partnership aims to enhance the market presence of Jaguar’s products while providing them with non-dilutive capital to support their rare-disease pipeline. Jaguar continues to manage the manufacturing of Mytesi and Canalevia-CA1, retaining strategic control over its products.
Read more →Jaguar Health has been awarded a $240,000 grant from the FDA to support its study of Canalevia-CA1, a treatment for chemotherapy-induced diarrhea (CID) in dogs. This grant follows the FDA's renewal of conditional approval for the drug for an additional year. With a significant number of dogs affected by CID, the study aims to address a critical need in veterinary medicine.
Read more →Jaguar Health announced that the FDA has renewed the conditional approval for Canalevia-CA1, a drug for treating chemotherapy-induced diarrhea in dogs, valid until December 21, 2026. The renewal is based on the company's progress in ongoing trials, which are expected to conclude in February 2026. Canalevia-CA1 is crucial for improving the quality of life for dogs undergoing cancer treatment.
Read more →Jaguar Health has announced the approval of all proposals at its December 2025 Special Meeting of Stockholders. The company shared positive preliminary results from an ongoing trial of crofelemer, which suggests potential benefits for infants with intestinal failure due to microvillus inclusion disease (MVID). Additionally, Jaguar is pursuing an expedited approval pathway for crofelemer, potentially expanding treatment options for this severe condition. Despite these advancements, the treatment carries safety concerns due to toxicity.
Read more →Jaguar Health, Inc. reported that all proposals were approved during its Annual Meeting of Stockholders on August 19, 2025. The meeting underscored positive developments, including promising initial results from ongoing clinical trials of crofelemer for patients with microvillus inclusion disease and short bowel syndrome. The company is advancing its regulatory strategy for a supplemental NDA to treat metastatic breast cancer in an orphan population. Jaguar's strategy also includes seeking partnerships to develop orphan indication products, which could bolster funding efforts.
Read more →Jaguar Health, Inc. has announced the extension of the maturity date for its convertible promissory notes from June 30, 2025, to January 30, 2026, allowing more time for financial management. This extension involves approximately $2.57 million in aggregate principal from a previous bridge financing. The CEO emphasized the importance of investor participation in supporting the company's core development programs for crofelemer, targeted towards various gastrointestinal issues in both humans and dogs. The move aims to enhance corporate partnerships and secure non-dilutive funding for ongoing projects.
Read more →Jaguar Health, Inc. announced a registered direct offering of 246,306 shares of common stock priced at $6.09 per share, aiming to raise approximately $1.5 million. In conjunction with this offering, Jaguar will issue unregistered warrants to investors for additional shares at an exercise price of $5.84. The proceeds from the offering are intended for general corporate purposes, including operational expenses and capital expenditures. The transaction is expected to close on or about May 22, 2025.
Read more →Jaguar Health has announced promising proof-of-concept results for crofelemer, indicating it can significantly reduce total parenteral nutrition (TPN) needs in patients suffering from microvillus inclusion disease (MVID) and short bowel syndrome with intestinal failure (SBS-IF). The results, presented at the Annual ELITE PED-GI Congress, show reductions in both TPN and fluid supplementation requirements by up to 27% and 12.5%, respectively. Furthermore, there is potential for crofelemer to enhance nutrient absorption and quality of life for patients who currently rely on TPN, an intervention that carries significant health risks. The findings could pave the way for expedited regulatory approvals in both the EU and the U.S.
Read more →Jaguar Health, Inc. has reported its first-quarter financial results for 2025, showing a decline in revenue and an increase in losses compared to the previous year. The company reported a combined net revenue of approximately $2.2 million, a decrease of 6% compared to the same quarter in 2024, and a further decline of 37% from the prior quarter. Despite these financial challenges, Mytesi prescription volume showed a slight increase year-over-year, and significant upcoming FDA discussions regarding crofelemer's Phase 3 trial outcomes provide a potential area of optimism.
Read more →Jaguar Health, Inc. plans to present initial results from a proof-of-concept study of crofelemer for treating Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome with Intestinal Failure (SBS-IF) during an investor webcast on April 30, 2025. The study, conducted by recognized pediatric gastroenterologist Dr. Mohamad Miqdady, is significant as there are currently no approved treatments for these rare diseases. The webcast will discuss the impact of crofelemer on patient quality of life and potential regulatory pathways for expedited approval. Additional results from other studies are anticipated throughout 2025.
Read more →Jaguar Health, Inc. (JAGX) has outlined its forward-looking statements regarding the development of crofelemer for various gastrointestinal disorders, including HIV-related diarrhea and short bowel syndrome. The company anticipates significant investment and support for its initiatives, including leveraging strategic partnerships and proprietary technologies. Initial studies indicate promising results for crofelemer in reducing nutritional support needs for certain patient populations, with potential designations from regulatory bodies that could enhance its market presence.
Read more →Jaguar Health, Inc. (NASDAQ: JAGX) recently outlined its forward-looking statements regarding the development and commercialization of crofelemer for various gastrointestinal disorders, including HIV-related diarrhea and short bowel syndrome. The company has several ongoing Phase 2 studies and is focusing on leveraging its proprietary medicinal plant library to potentially develop new therapies. Additionally, there is a pending investment from One Small Planet into Magdalena Biosciences for exploring plant-based alternatives for ADHD. Jaguar Health aims to capitalize on market opportunities for its products, projecting significant revenue potential in the coming years.
Read more →Jaguar Health, Inc. announced the closing of its private placement, raising approximately $3.448 million through convertible promissory notes. This financing is intended to support upcoming developments in crofelemer, which targets rare diseases and cancer therapy-related diarrhea. The notes issued will be convertible into shares of common stock and have a maturity of three months with a 6% interest rate. The company plans to use the proceeds for working capital and corporate purposes.
Read more →Jaguar Health reported a 20% increase in total net revenue for 2024, totaling approximately $11.7 million, with notable growth in both prescription and non-prescription products. The fourth quarter's revenue reached about $3.5 million, up 53% from the previous year's fourth quarter. The company is looking forward to upcoming proof-of-concept trial results for rare diseases in Q2 2025, alongside an FDA meeting regarding its Phase 3 OnTarget trial for crofelemer. Despite these positive developments, Jaguar continues to face significant net losses and rising sales and marketing expenses.
Read more →Jaguar Health, Inc. (NASDAQ:JAGX) announced a bridge financing round of $3.448 million involving its CEO, board members, and institutional investors. The financing consists of convertible promissory notes and is intended for working capital and general corporate purposes. Closing of the offering is expected on or around March 27, 2025. This financing demonstrates strong internal confidence in the company's future prospects and commitment from its leadership team.
Read more →Jaguar Health, Inc. has announced a reverse stock split of its common stock at an exchange ratio of 1-for-25, effective March 24, 2025. This action was approved at a Special Meeting of Stockholders to help the company meet Nasdaq's listing standards. Following the split, the company's shares will trade on a split-adjusted basis, with a new CUSIP number assigned to the stock. The CEO stated that the move aims to create a more attractive share price for institutional investors.
Read more →Jaguar Health, Inc. announced the approval of all proposals at its Special Meeting of Stockholders held on March 13, 2025. The company anticipates initial results from proof-of-concept trials for crofelemer in treating rare gastrointestinal diseases by Q2 2025, along with a significant FDA meeting regarding results from a Phase 3 trial focused on breast cancer patients. These developments underline Jaguar's commitment to advancing its treatment for conditions such as short bowel syndrome and microvillus inclusion disease, while also exploring regulatory pathways for potential approvals.
Read more →Jaguar Health, Inc. has implemented a limited duration stockholder rights plan to ensure its investors can realize long-term value amid ongoing stock price volatility. The company expects to report early results from proof-of-concept trials of its drug crofelemer for rare diseases in Q2 2025 and is preparing for a significant FDA meeting related to its Phase 3 clinical trial outcomes. Additionally, Jaguar has received indications of interest for acquisition, prompting the rights plan to secure the company's strategic direction and value for its shareholders.
Read more →Jaguar Health announced its third-quarter 2024 financial results, reporting a total net revenue of approximately $3.1 million, an increase of 14% from Q2 2024 and 11% from Q3 2023. The company highlighted significant findings from its Phase 3 OnTarget trial for crofelemer in breast cancer patients, which will be presented at a major conference in December 2024. Additionally, Jaguar is launching its third prescription product, Gelclair, and initiating two Phase 2 trials for crofelemer targeting rare diseases in multiple regions.
Read more →Jaguar Health, Inc. reported its Q2 2024 financial results, showcasing a combined net revenue of approximately $2.72 million, a 16% increase from Q1 2024. The company plans to commercialize Gelclair, its third prescription product, in October 2024, and is advancing clinical trials for crofelemer for rare conditions. In addition, there are plans to engage with the FDA regarding the approval pathways for crofelemer to support cancer patients experiencing treatment-related diarrhea. However, the company continues to face financial losses despite the revenue uptick.
Read more →Jaguar Health, Inc. reported the initial results of its Phase 3 OnTarget trial for crofelemer, a drug aimed at reducing diarrhea in cancer patients receiving targeted therapies. While the trial failed to meet its primary endpoint across all tumor types, there were improvements noted in specific subgroups, particularly among breast and respiratory cancer patients. Further analysis of additional data from the trial is anticipated, with plans for future discussions with the FDA regarding crofelemer's use in these patient populations.
Read more →Jaguar Health, Inc. announced that it has regained compliance with Nasdaq's minimum bid price requirement as of June 25, 2024. The company's president and CEO, Lisa Conte, expressed satisfaction with this achievement, considering the Nasdaq listing an asset. Jaguar is also preparing to report results from its pivotal phase 3 OnTarget trial for its cancer supportive care drug, crofelemer, on or before July 23, 2024. A webcast will be held to discuss ongoing advancements in the company’s portfolio, featuring members from their scientific team and oncology experts.
Read more →Jaguar Health announced the approval of all proposals submitted to stockholders during the June 2024 Annual Meeting. The company is set to report pivotal phase 3 OnTarget trial results for crofelemer, a drug intended for cancer therapy-related diarrhea, by July 23, 2024. They will also host an investor webcast featuring updates from their scientific team and oncology experts. Jaguar emphasizes its sustainability initiatives and highlights a recent podcast interview with ethnobotanist Dr. Steven King.
Read more →Jaguar Health, Inc. has announced a 1-for-60 reverse stock split of its common stock, set to take effect on May 23, 2024. This decision was approved by shareholders at a special meeting and aims to ensure compliance with Nasdaq's listing standards. The company believes the split will make its shares more appealing to institutional investors, thereby improving its market position. Following the split, common stock shares will trade on a split-adjusted basis, and no fractional shares will be issued.
Read more →Jaguar Health, Inc. (JAGX) announced the successful approval of all proposals during its Special Meeting of Stockholders on April 9, 2024. The company is focusing on its Phase 3 OnTarget trial of crofelemer aimed at preventing cancer therapy-related diarrhea, with top line results expected soon. Additionally, Jaguar received an extended grace period from Nasdaq to meet its share price requirements, opting not to proceed with a reverse stock split at this time.
Read more →Jaguar Health, Inc. (NASDAQ: JAGX) has entered a binding commercialization agreement with Turkish pharmaceutical company GEN, which includes a $2 million investment in Jaguar stock at a 75% premium. This partnership grants GEN exclusive rights to license and market crofelemer, an FDA-approved drug for HIV-related diarrhea, in Turkey and eight neighboring countries. The agreement also involves double-digit royalties for Jaguar on all sales in the licensed territory. This collaboration aims to address significant unmet medical needs across various indications, enhancing access to essential therapies in the region.
Read more →Jaguar Health, Inc. received a 180-day grace period from Nasdaq to comply with its $1.00 bid price requirement, extending the deadline to May 6, 2024. The company meets all other listing requirements and aims to show compliance by reporting a closing bid price of $1.00 or more for at least ten consecutive business days. Jaguar is concurrently engaged in clinical trials for Mytesi, with top line results from the OnTarget trial anticipated before Thanksgiving. The company is also conducting studies for crofelemer targeting rare diseases in multiple geographical regions.
Read more →Jaguar Health, Inc. has reported its Q2 2023 financial results, highlighting a 36% increase in net revenue compared to Q1 2023, totaling approximately $2.7 million. However, the company experienced a growth in operational losses, which increased by $1.6 million year-over-year. Jaguar is advancing its Phase 3 OnTarget trial for crofelemer, with top-line results anticipated in late October 2023. Additionally, the company is exploring treatments for rare diseases short bowel syndrome and microvillus inclusion disease, with results from related studies expected soon.
Read more →Jaguar Health, Inc. announced the successful approval of all five proposals at its 2023 Annual Meeting of Stockholders held on July 7, 2023. This outcome reflects strong support from stockholders for the company's initiatives. Jaguar Health is dedicated to creating novel, plant-based prescription medicines aimed at alleviating gastrointestinal distress. Additionally, the company is expanding its crofelemer drug product in European markets through Napo Therapeutics.
Read more →Jaguar Health, Inc. has announced the replenishment of its New Employee Inducement Award Plan with 499,171 shares of common stock. This plan is designed to attract new employees by providing equity awards to individuals who have not been previously associated with the company. This replenishment is a strategic move as Jaguar Health continues to focus on developing sustainable, plant-based pharmaceuticals targeting gastrointestinal distress. The announcement reflects the company's ongoing efforts to grow its workforce and expand its product impact.
Read more →Jaguar Health reported its first quarter 2023 financial results, revealing a decrease in net revenue of approximately 40% compared to the previous quarter and a 25% decline from the same period last year. However, the company noted an improvement in its net loss, which decreased from $11.8 million in Q1 2022 to $9.8 million in Q1 2023. To strengthen its financial position, Jaguar secured $1.86 million from a recent PIPE transaction and aims to prioritize patient engagement to facilitate the growth of its Mytesi product. The completion of patient enrollment for the Phase 3 OnTarget trial is also a promising development, with top-line results expected in October 2023.
Read more →Jaguar Health, Inc. has completed enrollment of 256 patients in its Phase 3 OnTarget clinical trial of crofelemer for cancer therapy-related diarrhea. The primary endpoint results, based on patient-reported outcomes, are expected to be released in October 2023. The company also announced a PIPE financing agreement that involves a significant investment from long-term investors, which is aimed at funding ongoing operations and the trial. This milestone represents a key step in Jaguar's mission to provide solutions for patients experiencing diarrhea from cancer treatments.
Read more →Jaguar Health, Inc. reported significant growth in prescription revenues for the year ended December 31, 2022, with an increase of approximately 178.7% compared to the previous year, totaling around $11.9 million. Patient enrollment in the Phase 3 OnTarget trial of crofelemer reached 80%, with completion expected in the second quarter of 2023. The company is also planning to launch proof-of-concept studies for crofelemer in 2023 targeting short bowel syndrome and congenital diarrheal disorders. However, total prescription volume for Mytesi slightly decreased, and the company reported a net loss of $48.4 million for the year.
Read more →Jaguar Health, Inc. has announced that it has regained compliance with Nasdaq's minimum bid price requirement as of February 7, 2023. The company's president and CEO expressed satisfaction regarding this compliance and highlighted two key late-stage clinical events expected to occur in the next six months, which they anticipate will enhance the company's value and recognition. The completion of enrollment for the OnTarget trial is expected by the second quarter of 2023, alongside a proof-of-concept trial related to related disorders.
Read more →Jaguar Health and SynWorld Technologies have mutually agreed to terminate the Canalevia license agreement for treating diarrhea in dogs in China, effective January 31, 2023. This decision aligns with Jaguar's strategic focus on human drug development, particularly its Phase 3 OnTarget trial for cancer therapy-related diarrhea. Jaguar anticipates this focus will lead to transformational value creation within the next six months. Both companies may explore future opportunities related to Canalevia depending on market demand in China.
Read more →Jaguar Health, Inc. announced the results of its January 2023 Special Meeting of Stockholders, where stockholders approved three proposals, including a 1-for-75 reverse stock split to comply with Nasdaq listing standards. The reverse stock split will take effect on January 23, 2023, allowing the company to continue trading under its current symbol, 'JAGX.' Jaguar is also poised to complete enrollment in its pivotal Phase 3 OnTarget clinical trial for crofelemer by Q2 2023, as it focuses on developing the drug for the prophylaxis of diarrhea related to cancer therapies.
Read more →Jaguar Health Provides Company Updates and Reports 2022 Third Quarter Financials Prescription product net revenue of approximately $3.1 million in Q3 2022 increased 8.2% over Q2 2022 and increased approximately 412% over prescription product net revenue in Q3 2021 Phase 3 cli
Read more →Jaguar Health Reports Voting Results from 2022 Special Meeting of Stockholders All Proposals Approved Francisco, CA (September 30, 2022): Jaguar Health, Inc. (NASDAQ: JAGX) ("Jaguar" or the "Company") today announced the voting results of the Company's 2022 Special Meeting of
Read more →Health Secures Additional Capital Through Sale of Royalty Rights Related to Future Crofelemer and Lechlemer Revenue Stream proceeds will be allocated to support the company's ongoing OnTarget pivotal Phase 3 clinical trial of crofelemer for prophylaxis of diarrhea in adults rec
Read more →Jaguar Health Appoints Senior Healthcare and Investment Executive Dr. Anula Jayasuriya to Board of Directors and Forms Business Development Advisory Committee to Assess Opportunities for Alliances, Mergers, and Acquisitions Greg Divis departs from Jaguar's Board of Directors;
Read more →Enters Exclusive Crofelemer License and Commercialization Agreement with SynWorld Technologies for Canalevia for Treatment of Diarrhea of $5.0 million, and up to $5.0 million in unregistered equity infusion, over next 24 months of up to $5.0 million payable in unregistered Jagu
Read more →Jaguar Health Reports Voting Results from 2022 Annual Meeting of Stockholders All Proposals Approved Francisco, CA (June 10, 2022): Jaguar Health, Inc. (NASDAQ: JAGX) ("Jaguar" or the "Company") today announced the voting results of the Company's 2022 Annual Meeting of Stockh
Read more →Jaguar Health Provides Company Updates and Reports 2022 First Quarter Financials Mytesi net revenue of $2.6 million increased approximately 24% over the fourth quarter of 2021 and increased approximately 112% over Mytesi net revenue in the first quarter Phase 3 clinical trial
Read more →Provides Company Updates and Reports 2021 Financials Core 2022 development initiatives: operation of Company's OnTarget Phase 3 clinical trial of crofelemer for prophylaxis of cancer therapy-related diarrhea (CTD) and completion in 2H 2022 of investigator-initiated proof-of-
Read more →Reports 2021 Third Quarter Financial Results prescription volume increased 7.6% in Q3 2021 over Q2 2021 2021 Mytesi net and gross sales were approximately $0.6 million and approximately $3.2 million to complete transition to selling Mytesi through closed specialty pharmacy net
Read more →Announces Closing of Private Placement Priced at a Premium to Market Participating investors include Jaguar CEO and CFO, Dragon SPAC S.p.A. sponsor Josh Mailman, and plant-based pharmaceutical manufacturing pioneer Indena S.p.A. to host investor webcast Monday, September 20th
Read more →Jaguar Health Reports Voting Results from 2021 Annual Meeting of Stockholders Proposals 1, 2, 4, 5 & 6 approved San Francisco, CA (September 3, 2021): Jaguar Health, Inc. (NASDAQ: JAGX) ("Jaguar" or the "Company") today announced the voting results of the Company's May 13, 20
Read more →Jaguar Health Subsidiary Napo Pharmaceuticals Agreement with its Italian Subsidiary, Napo EU S.p.A., to Develop and Commercialize Crofelemer and Lechlemer in Europe Per the terms of the agreement, Napo Pharmaceuticals will receive an upfront payment of $10 million payable in
Read more →Announces Adjournment of Annual Meeting of Stockholders Until Friday, September 3, 2021 and Encourages All Shareholders to Vote Based on a preliminary review of votes cast, over 75% have voted in favor of Proposals 2, 3, 4 & 6 Meeting scheduled to reconvene September 3, 2021
Read more →EU S.p.A., Jaguar Health's Italian Subsidiary, and Dragon SPAC S.p.A. Announce Close of 8,830,000 Euro Dragon SPAC Financing EU, the identified target of Dragon SPAC, seeks to develop plant-based crofelemer to potentially treat orphan disease - short bowel syndrome (crofeleme
Read more →Jaguar Health & Dragon SPAC Announce Initial Funding of US$10.8 Million into Dragon SPAC Napo EU S.p.A., named target of Dragon SPAC, provides update on plan to pursue conditional marketing authorization for crofelemer in EU Equita Group S.p.A., a leading Italian based inves
Read more →Jaguar Health, Inc. Reports 2021 First Quarter First quarter 2021 Mytesi gross sales and net sales were approximately $4.6 million and approximately $1.2 million, increases of 250% and 43%, respectively Company to host investor webcast Monday, May 17th at 8:30 a.m. Eastern re
Read more →to Host Investor Webcast Monday, May 17th at 8:30 AM Eastern Time Regarding Q1 2021 Financials & Business Updates Webcast registration link appears below Company plans to file Q1 2021 10-Q on May 17, San Francisco, CA (May 11, 2021): Jaguar Health, Inc. (NASDAQ: JAGX) ("Jagu
Read more →Jaguar Health Announces $10.8 Million Registered Offering for the Benefit of Napo EU Business Plan Company terminates at-the-market (ATM) financing San Francisco, CA (April 29, 2021): Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced it has entered
Read more →Jaguar Health Announces Upsizing of At-the-Market (ATM) Financing Program by $15.3 Million with Ladenburg Thalmann & Co. Inc. for Potential Future Financing Needs Merger of Napo EU and Dragon SPAC targeted for Jaguar kicks off educational awareness contest in honor of HIV Lon
Read more →Promotes Carol Lizak to Chief Financial Officer SAN FRANCISCO, CA / April 6, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") announced today that the Company has promoted Carol Lizak, an accomplished financial executive, to the expanded role of chief finan
Read more →Jaguar Health Reports 2020 Financial Results and Business Updates Mytesi net sales and gross sales grew 64% and 148%, respectively, in 2020 compared to 2019 SAN FRANCISCO, CA / March 31, 2021 / Jaguar Health, Inc. (NASDAQ: JAGX) ("Jaguar" or the "Company") today reported consol
Read more →Jaguar Health Signs Definitive Agreement dilutive Financing Transaction Involving Sale of Royalty Rights Related to Future Potential Crofelemer (Mytesi) COVID-related Indication Revenue Stream No royalty payments due for 36 months Company has started to identify key opinion
Read more →Jaguar Health Announces Closing of $6.0 Million Issuance and Sale of Designation-backed Note Related to Possible Tropical Disease Priority Review Voucher This additional non-dilutive financing will support development program for lechlemer for the indication of the symptomatic r
Read more →Jaguar Health Announces $15 Million Registered Direct Offering Priced Above-the-Market Under Nasdaq Rules San Francisco, CA (January 13, 2021): Jaguar Health, Inc. (NASDAQ:JAGX) ( Jaguar or the Company ) today announced it has entered into a securities purchase agreement with tw
Read more →Jaguar Health Exploring Possibility of Conditional Marketing Authorization for Proposed Inflammatory Diarrhea Indication for Crofelemer, Initially in Long-Hauler COVID-19 Recovery Patients in Europe New COVID-19 strain estimated to have tripled number of infections in England du
Read more →Jaguar Health Reports Voting Results from Special Meeting of Stockholders & Announces December 23rd Investor Webinar All proposals approved Company not implementing a reverse split at this time Swiss Growth Forum hosting investor webinar Wednesday, December 23rd at 10:30 AM Ea
Read more →Jaguar Health and its Subsidiary, Napo Pharmaceuticals, Enter into Fifth Amendment to the Accounts Receivable Purchase Agreement with Oasis Capital, LLC, Dated May 12, 2020 The Sixth Tranche Accounts Receivable has a gross value of $3,810,587.04, representing customer billings o
Read more →Jaguar Health Announces Plan to Develop and Commercialize Crofelemer, the Company's Novel Proprietary Drug, for the Indication of Inflammatory Diarrhea, Initially in Long-Hauler' COVID-19 Recovery Patients A significant percentage of COVID-19 recovery patients suffer from lon
Read more →Health, Inc. Reports 2020 Third Quarter Financial Results Third quarter 2020 Mytesi net sales and gross sales were approximately $2.8 million and approximately $6.3 million, respectively Company to host investor call Monday, November 16th at 8:30 a.m. Eastern regarding third
Read more →Health to Host Investor Call Monday, November 16th at 8:30 a.m. Eastern Regarding Q3 2020 Financials & Business Updates Company Plans to File Q3 2020 10-Q on San Francisco, CA (November 10, 2020): Jaguar Health, Inc. (NASDAQ: JAGX) ("Jaguar" or the "Company") today announced t
Read more →Jaguar Health Receives Positive Nasdaq Listing Determination San Francisco, CA (October 29, 2020): Jaguar Health, Inc. (NASDAQ: JAGX) ( Jaguar or the Company ) today announced that on October 28, 2020 the Company received formal notice that the Nasdaq Hearings Panel (the Panel
Read more →Jaguar Health Provides Updates Regarding Company Capitalization Strategy Jaguar Has Closed on the First $6 Million Tranche of the Previously Announced Non-Dilutive Royalty Financing Transaction - Which Now Has the Potential to Total $17 Million Jaguar and its Subsidiary, Napo P
Read more →Jaguar Health Signs Agreement for Non-dilutive Financing Transaction Involving the Sale of Royalty Rights Related to Future Mytesi (Crofelemer) Revenue Stream for $5 Million, with Possible Future Tranches in 2021, Totaling $16 Million Proceeds Will Be Allocated to Support Reg
Read more →Jaguar Health, Inc. (NASDAQ: JAGX) Overview September 2020 Forward-Looking Statements 2 This presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding the Company s pl
Read more →Jaguar Health and its Subsidiary, Napo Pharmaceuticals, Enter into Third Amendment to the Accounts Receivable Purchase Agreement with Oasis Capital, LLC, Dated May 12, 2020 The Fourth Tranche Accounts Receivable has a gross value of $2,329,662.72, representing customer billings
Read more →Jaguar Health Completes Transactions that Increase Stockholders Equity Above $5,000,000 Amount Exceeds Minimum Stockholders Equity Requirement for Initial Listing on The Nasdaq Capital Market SAN FRANCISCO, CA / September 2, 2020 / Jaguar Health, Inc. (Nasdaq: JAGX) ( Jaguar or
Read more →Jaguar Health and its Subsidiary, Napo Pharmaceuticals, Enter into a Second Amendment to the Accounts Receivable Purchase Agreement with Oasis Capital, LLC, Dated May 12, 2020 SAN FRANCISCO, CA / August 14, 2020 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Jaguar and
Read more →Jaguar Health, Inc. Reports 2020 Second Quarter Financial Results Q2 2020 Mytesi net sales and gross sales were approximately $3.2 million and approximately $6.3 million, respectively Reminder: Company to host investor call Thursday, August 13th at 8:30 a.m. Eastern regarding Q
Read more →Jaguar Health to Host Investor Call August 13th at 8:30 a.m. Eastern Regarding Q2 2020 Financials & Business Updates Company Plans to File Q2 2020 10-Q on August 13, 2020 Save the Date: Company to host virtual disease awareness event on October 20, 2020 focused on cancer ther
Read more →Jaguar Health Announces Activation of Investigational New Drug (IND) for Crofelemer (Mytesi) for Prophylaxis and Symptomatic Relief of Cancer Therapy-Related Diarrhea A significant proportion of patients undergoing cancer therapy experience diarrhea San Francisco, CA (August 6,
Read more →Jaguar Health Reports Voting Results from July 21, 2020 Special Meeting of Stockholders All Proposals Approved San Francisco, CA (July 21, 2020): Jaguar Health, Inc. (NASDAQ: JAGX) ( Jaguar or the Company ) today announced the voting results from the Special Meeting of Stockhol
Read more →Health and its Subsidiary, Napo Pharmaceuticals, Enter an Amendment to the Accounts Receivable Purchase Agreement with Oasis Capital, LLC, Dated May 12, 2020 Additional spring 2020 sales of Mytesi (beyond April 2020 sales) generate gross accounts receivable of $2,859,132 SAN
Read more →Jaguar Health, Inc. Reports 2020 First Quarter Financial Results Reminder: Company to host investor call today at 8:30 a.m. Eastern SAN FRANCISCO, CA / May 15, 2020 / Jaguar Health, Inc. (NASDAQ: JAGX) ( Jaguar or the Company ) today reported consolidated first quarter 2020 fin
Read more →Jaguar Health to Host Investor Call May 15th at 8:30 a.m. Eastern Regarding Q1 2020 Financials & Business Updates Company Plans to File Q1 2020 10-Q on May 14, 2020 San Francisco, CA (May 12, 2020): Jaguar Health, Inc. (NASDAQ: JAGX) ( Jaguar or the Company ) today announced t
Read more →Jaguar Health and its Subsidiary, Napo Enter Accounts Receivable Purchase Agreement with Oasis April 2020 sales of Mytesi generate gross accounts receivable of $2,753,639 SAN FRANCISCO, CA / May 13, 2020 / Jaguar Health, Inc. (NASDAQ: JAGX) today announced that Jaguar and it
Read more →Jaguar Health Statement on Mytesi (crofelemer) April 2020 Price Adjustment and Commitment to Ensuring People Living with HIV Have Uninterrupted Access to Only FDA-Approved Non-Opioid, Plant-based, Anti-diarrheal Medication The following provides important context regarding our
Read more →Jaguar Health Enters Deal with Atlas Sciences to Develop NP-500, a Jaguar Non-Core Plant-based Type II Diabetes Drug Candidate Jaguar concurrently receives $1.5 million and exclusive 10-year license from purchaser to develop and commercialize NP-500 through sale of NP-500 techno
Read more →Jaguar Health Reports 2019 Financial Results and Business Updates Mytesi net sales and gross sales grew 38% and 44%, respectively, in 2019 compared to 2018 Reminder: Company to host investor call Monday, April 6 at 8:30 a.m. Eastern SAN FRANCISCO, CA / April 6, 2020 / Jagua
Read more →Health to Host Investor Call April 6th at 8:30 a.m. Eastern Regarding Q4 2019 Financials & Business Updates Company Filed its Annual Report on April 3, 2020 on Form 10-K for the Fiscal Year Ended December 31, 2019 Francisco, CA (April 3, 2020): Jaguar Health, Inc. (NASDAQ: JAGX
Read more →Jaguar Health Secures Non-dilutive Capital Through Sale of Royalty Rights Related to Future Mytesi Revenue Stream Transaction Proceeds Will be Allocated to Support Advancement of Regulatory Activities Associated with Jaguar's Pipeline, Including the Company's Lead Product Can
Read more →DIRECTOR RESIGNATION Jaguar Health, Inc. (the "Company") Effective as of February 21, 2020 As the Company is aware, the holders of Series A Preferred Stock have ceased to beneficially own at least five percent of the outstanding voting securities of the Company, on an as-con
Read more →Jaguar Health Announces that Interim Analysis Requirement Met in Phase 2 HALT-D Study Evaluating Mytesi (Crofelemer) for Prevention and Prophylaxis of Diarrhea in Breast Cancer Patients San Francisco, CA (November 14, 2019): Jaguar Health, Inc. (NASDAQ: JAGX) ( Jaguar or the Com
Read more →Jaguar Health to Host Investor Call Nov. 14th at 9 a.m. Eastern Regarding Interim Analysis of HALT-D Study of Mytesi (Crofelemer) for Prevention of Diarrhea in Breast Cancer Patients, Q3 Financials & Business Updates Company Plans to File Q3 2019 10-Q on November 14, 2019 San F
Read more →Jaguar Health, Inc. Reports 2019 Third Quarter Financial Results Reminder: Company to Host Investor Call Today at 9 a.m. Eastern Regarding Interim Analysis of HALT-D Study of Mytesi (Crofelemer) for Prevention of Diarrhea in Breast Cancer Patients, Q3 Financials & Business Updat
Read more →Jaguar Health Eliminates Certain Royalty Obligations Reducing Future COGS for Mytesi and Crofelemer San Francisco, CA (October 4, 2019): Jaguar Health, Inc. (NASDAQ: JAGX) ( Jaguar or the Company ), today announced that a License Termination and Settlement agreement ( LTSA ) rel
Read more →Jaguar Health Promotes Jonathan Wolin to Chief of Staff, Chief Compliance Officer & General Counsel San Francisco, CA (September 9, 2019): Jaguar Health, Inc. (NASDAQ: JAGX) ( Jaguar or the Company ) announced today that the Company has promoted Jonathan Wolin, an accomplished h
Read more →Jaguar Health Appoints Carol Lizak Chief Accounting Officer San Francisco, CA (August 16, 2019): Jaguar Health, Inc. (NASDAQ: JAGX) ( Jaguar or the Company ), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on
Read more →Jaguar Health, Inc. Reports 2019 Second Quarter Financial Results Mytesi Net Sales and Gross Mytesi Sales Grew 102% and 93%, Respectively, in Q2 2019 Compared to Q2 2018 SAN FRANCISCO, CA / August 14, 2019 / Jaguar Health, Inc. (NASDAQ: JAGX) ( Jaguar or the Company ), a commer
Read more →Jaguar Health Announces Pricing of $14.4 Million Underwritten Public Offering San Francisco, CA (July 19, 2019): Jaguar Health, Inc. (NASDAQ: JAGX) ( Jaguar or the Company ), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointesti
Read more →Jaguar Health Strengthens Company s Balance Sheet by Reducing Approximately $10.5 Million of Debt Incurred to Effect 2017 Merger to Approximately $4.4 Million Maturity Date of Remaining Merger-related Debt is December 31, 2020 San Francisco, CA (July 15, 2019): Jaguar Health, I
Read more →Jaguar Health Strengthens Company s Balance Sheet by Reducing Approximately $10.5 Million of Debt Incurred to Effect 2017 Merger to Approximately $5.7 Million Maturity Date of Remaining Merger-related Debt is December 31, 2020 San Francisco, CA (June 28, 2019): Jaguar Health, I
Read more →Jaguar Health Regains Compliance with All Applicable Nasdaq Stock Market Listing Standards San Francisco, CA (June 24, 2019): Jaguar Health, Inc. (NASDAQ: JAGX) ( Jaguar or the Company ), a commercial stage pharmaceutical company focused on developing novel, sustainably derived
Read more →Jaguar Health CEO and Board Members Invest in Bridge Financing San Francisco, CA (June 5, 2019): Jaguar Health, Inc. (NASDAQ: JAGX) ( Jaguar or the Company ), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on
Read more →Jaguar Health Refinances $10.5 Million of Secured Debt, Including an Extension of the Maturity of Such Debt from December 31, 2019 to December 31, 2020 San Francisco, CA (June 3, 2019): Jaguar Health, Inc. (NASDAQ: JAGX) ( Jaguar or the Company ), a commercial stage pharmaceutic
Read more →Jaguar Health Eliminates More Than $6.4 Million in Secured Promissory Notes to Strengthen Company s Balance Sheet San Francisco, CA (May 29, 2019): Jaguar Health, Inc. (NASDAQ: JAGX) ( Jaguar or the Company ), a commercial stage pharmaceutical company focused on developing novel
Read more →Jaguar Health, Inc. Reports Voting Results from May 24, 2019 Annual Meeting of Stockholders All Proposals Approved San Francisco, CA (May 24, 2019): Jaguar Health, Inc. (NASDAQ: JAGX) ( Jaguar or the Company ), a commercial stage pharmaceutical company focused on developing nov
Read more →Jaguar Health, Inc. Reports 2019 First Quarter Financial Results Mytesi Net Sales and Gross Sales Grew 154% and 161%, Respectively, in Q1 2019 Compared to Q1 2018 SAN FRANCISCO, CA / May 24, 2019 / Jaguar Health, Inc. (NASDAQ: JAGX) ( Jaguar or the Company ), a commercial stage
Read more →Jaguar Health, Inc. Reports 2018 Fourth Quarter and Year End Financial Results Mytesi Gross Sales and Net Sales Grew 237% and 185%, Respectively, in the Year End 2018 Compared to Year End 2017 SAN FRANCISCO, CA / April 10, 2019 / Jaguar Health, Inc. (NASDAQ: JAGX) ( Jaguar or t
Read more →Jaguar Health Announces Adjournment of Special Meeting of Stockholders Until Thursday, February 28, 2019 San Francisco, CA (February 25, 2019): Jaguar Health, Inc. (NASDAQ: JAGX) ( Jaguar or the Company ), a commercial stage pharmaceutical company focused on developing novel, su
Read more →Jaguar Health, Inc. Investor Presentation January 2019 Forward-Looking Statements This presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding the Company s plan to
Read more →Jaguar Health Provides Fourth Quarter 2018 Commercial Sales Updates Napo Pharmaceuticals, Inc., Jaguar s Wholly-owned Human Health Subsidiary, Expected to Achieve 40% Net Sales Growth for Mytesi (Crofelemer) in Q4 18 Versus Q3 18 SAN FRANCISCO, CA / January 7, 2019 / Jaguar Hea
Read more →Jaguar Health to Host Investor Call January 7th at 8 a.m. Eastern to Review 4Q 18 Performance San Francisco, CA (January 2, 2019): Jaguar Health, Inc. (NASDAQ: JAGX) ( Jaguar or the Company ), a commercial stage pharmaceutical company focused on developing novel, sustainably de
Read more →Jaguar Health, Inc. Reports Third-Quarter 2018 Results Mytesi Gross Sales and Net Sales Grew 36% and 28%, Respectively, in the Third Quarter of 2018 Compared to the Second Quarter of 2018 Company to Host Conference Call Thursday, November 15, 2018 at 8:00 a.m. Eastern Time to R
Read more →Jaguar Health, Inc. Expects to File Third-Quarter 2018 Financial Results November 14th Company to Host Conference Call Thursday, November 15, 2018 at 8:00 a.m. Eastern Time to Review Q3 Results and Provide Updates Regarding Mytesi Commercial, Educational & Product Development Ac
Read more →Jaguar Health Announces Pricing of $9 Million Underwritten Public Offering San Francisco, CA October 2, 2018 Jaguar Health, Inc. (Nasdaq: JAGX) ( Jaguar or the Company ), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal
Read more →Jaguar Health, Inc. Investor Presentation September 2018 This presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding the Company s belief that Lechlemer may offer a
Read more →Knight Therapeutics and Jaguar Health Announce Strategic Partnership Knight receives license to Mytesi and related products in Canada and Israel MONTREAL, QC, and SAN FRANCISCO, CA September 24, 2018 Knight Therapeutics Inc. (TSX: GUD) ( Knight ), a Canadian-based specialty ph
Read more →Jaguar Health, Inc. Provides Second Quarter 2018 Financial Updates Napo Pharmaceuticals, Inc., Jaguar s wholly-owned human health subsidiary, achieved 47% gross sales growth for Mytesi (crofelemer) in the second quarter of 2018 versus the first quarter of 2018 SAN FRANCISCO, CA
Read more →Jaguar Health (NASDAQ: JAGX) Subsidiary Napo Pharmaceuticals and RedHill Biopharma Enter U.S. Co-Promotion Agreement for Mytesi, Napo s FDA-Approved Drug Product RedHill (NASDAQ: RDHL) has been granted the exclusive right to co-promote Mytesi (crofelemer 125 mg delayed-release t
Read more →Jaguar Health Appoints Pharmaceutical Industry Veteran David MacNaughtan to Board of Directors Separately, Jaguar has received notification that the Company is now in compliance with Nasdaq s listing standards San Francisco, CA (June 20, 2018): Jaguar Health, Inc. (NASDAQ: JAGX
Read more →Jaguar Health Appoints Senior Commercial Pharmaceutical Executive Greg Divis to Board of Directors San Francisco, CA (June 18, 2018): Jaguar Health, Inc. (NASDAQ: JAGX) ( Jaguar or the Company ), a commercial stage natural-products pharmaceutical company focused on developing no
Read more →Jaguar Health, Inc. Announces 1-for-15 Reverse Stock Split Shares of Common Stock Begin Trading on Split-Adjusted Basis on June 1, 2018 San Francisco, CA (June 1, 2018): Jaguar Health, Inc. (NASDAQ: JAGX) ( Jaguar or the Company ), a commercial stage natural-products pharmaceut
Read more →Jaguar Health Appoints Robert J. Griffing Chief Commercialization Officer of Jaguar Subsidiary Napo Pharmaceuticals Mr. Griffing to Lead Commercialization Efforts for Mytesi, Jaguar s FDA-Approved, First-in-Class Drug Product San Francisco, CA (May 29, 2018): Jaguar Health, Inc
Read more →Severance Plan Benefits for Section 16 Officers** 1 Current Section 16 officers: CEO, CFO, EVP Sustainable Supply, Ethnobotanical Research and IP Proposed Severance Benefits: One year annual salary (i) for termination of employment not for cause or (ii) for change of control (i.e
Read more →Jaguar Health, Inc. Reports First-Quarter 2018 Operational Updates and Voting Results from 2018 Annual Meeting of Stockholders Company Management to Host Conference Call Monday, May 21st at 4:30 p.m. Eastern Time for Investors and Analysts San Francisco, CA (May 18, 2018): Jagu
Read more →Jaguar Health Appoints Jonathan B. Siegel to Board of Directors San Francisco, CA (April 2, 2018): Jaguar Health, Inc. (NASDAQ: JAGX) ( Jaguar or the Company ), a commercial stage natural-products pharmaceutical company focused on developing novel, sustainably derived gastrointe
Read more →Jaguar Health Announces Up to $16.2 Million in Equity Financings in Separate Private Placement Investments, Including Investment By Sagard Capital Partners, L.P., to Continue Commercialization of FDA-Approved Mytesi Largest Investor Locked In for 12 Months San Francisco, CA (Ma
Read more →Jaguar Health Subsidiary Napo Pharmaceuticals Signs Agreement with Pharmacy Services Provider Transition Patient Services to Establish Nationwide Pilot Mytesi Direct Program San Francisco, CA (March 2, 2018): Jaguar Health, Inc. (NASDAQ: JAGX) (Jaguar or the Company), a commerci
Read more →Jaguar Health Provides Updates Regarding Commercial, Educational & Product Development Programs and 2017 Results for Mytesi Since Merger (August December 2017) Mytesi Sales Increased 17.71% Each Month Over the Prior Month San Francisco, CA (January 22, 2017): Jaguar Health, Inc
Read more →Jaguar Health to Host Conference Call Monday, January 22nd at 4:15 p.m. Eastern Time to Provide Updates Regarding Jaguar and Napo Pharmaceuticals Commercial, Educational & Product Development Activities and 2017 Results San Francisco, CA (January 18, 2018): Jaguar Health, Inc. (
Read more →Jaguar Health and Dubai-based Seed Mena Enter Collaboration Agreement for Equilevia, Jaguar s Personalized, Premium Product for Total Gut Health and Wellness in Horses San Francisco, CA (December 14, 2017): Jaguar Health, Inc. (NASDAQ: JAGX) (Jaguar), a natural-products pharma
Read more →Jaguar Health Announces Adjournment of Special Meeting of Stockholders Until Friday, December 15, 2017 San Francisco, CA (December 1, 2017): Jaguar Health, Inc. (NASDAQ: JAGX) (Jaguar or the Company), a commercial stage natural-products pharmaceuticals company focused on develop
Read more →Jaguar Health Enters Share Purchase Agreement for 2 Million Shares and Common Stock Purchase Agreement Relating to a 10 Million Share Equity Line Offering with L2 Capital, LLC Registered Direct at $0.25 Per Share and Equity Line at Fixed Price of $0.52 Per Share San Francisco,
Read more →Jaguar Health Files First Quarterly Earnings Report Since July 2017 Merger with Napo Pharmaceuticals As a Result of the Merger, Jaguar Shows Positive Net Income for Q3 2017 San Francisco, CA (November 20, 2017): Jaguar Health, Inc. (NASDAQ: JAGX) (Jaguar or the Company), a comm
Read more →Year-to-Date Gross Sales for Mytesi, the FDA-Approved Human Prescription Drug Product of Jaguar Health s Wholly-Owned Subsidiary, Napo Pharmaceuticals, Total $2.8 Million Expansion of National Salesforce Continues for Mytesi as Napo Significantly Ramps Up Post-Merger Product Com
Read more →Jaguar Health to Host Earnings Conference Call Tuesday, November 14th at 4:30 p.m. Eastern Time First Post-Merger Earnings Call for Jaguar and its Wholly-Owned Subsidiary, Napo Pharmaceuticals, Regarding Sales of Napo s FDA-Approved Human Drug, Mytesi, an Antidiarrheal Indicated
Read more →Jaguar Health Prices $4.25 Million Public Offering of Common Stock San Francisco, CA (September 29, 2017): Jaguar Health, Inc. (NASDAQ: JAGX) ( Jaguar or the Company ), a natural-products pharmaceuticals company focused on developing and commercializing novel, sustainably derive
Read more →Jaguar Subsidiary Napo Pharmaceuticals and Glenmark Pharmaceuticals Sign Agreement Returning Key Rights in 141 Countries to Napo, Solidifying Jaguar s Global Commercial Control of Mytesi (Crofelemer), Jaguar s FDA-Approved Human Drug Glenmark Will Continue to Serve as the cGMP-c
Read more →Jaguar Health Subsidiary Napo Pharmaceuticals Expands Mytesi Salesforce with Hire of Experienced HIV & GI Drug Sales Reps in Key U.S. Markets New Reps Will Target Physicians and Gastroenterologists Who Treat Large Numbers of HIV Patients San Francisco, CA (September 15, 2017):
Read more →Napo Pharmaceuticals, Inc. Condensed Consolidated Balance Sheets June 30, 2017 (Unaudited) December 31, 2016 Assets Current assets: Cash and cash equivalents $ 449,649 $ 2,271,745 Accounts receivable, net of allowance for doubtful accounts of $32,798 and $184,6
Read more →Jaguar Health Company Name Now Updated on Nasdaq.com Post-Merger Jaguar s Post-Merger Market Cap Expected to be Updated on Nasdaq.com and Other Web-based Financial Data Platforms Later this Month San Francisco, CA (August 16, 2017): Jaguar Health, Inc. (NASDAQ: JAGX) (Jaguar),
Read more →Napo Pharmaceuticals, Inc. Index to Consolidated Financial Statements Page Unaudited Interim Financial Statements Condensed Consolidated Balance Sheets as of March 31, 2017 and December 31, 2016 1 Condensed Consolidated Statements of Operations for the Three Month Per
Read more →The Merger of Jaguar Animal Health and Napo Pharmaceuticals is Effective The Combined Company s New Name is Jaguar Health, Inc. Nasdaq Ticker Remains the Same: JAGX Merger Terms Include Additional Funding for Combined Company at $0.925/share as Disclosed in the Proxy/Prospect
Read more →Stockholders of Jaguar Animal Health and Napo Pharmaceuticals Vote to Approve Merger Merger Terms Include Funding for Combined Company and Other Aspects of the Merger Disclosed in the Proxy/Prospectus Jaguar to Host Conference Call Friday, July 28th at 8:30 a.m. Eastern Time S
Read more →Jaguar Animal Health to Hold Special Meeting of Stockholders July 27, 2017 to Vote Upon the Consummation of its Proposed Merger with Napo Pharmaceuticals, Inc. Terms of Proposed Merger Include Funding for Combined Company and Other Aspects of the Merger Disclosed in the Proxy
Read more →General Overview June 2017 This presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding the proposed merger between Jaguar and Napo and the expectation that the merg
Read more →Jaguar Signs Distribution Agreement for Japan for Neonorm Foal & Neonorm Calf Jaguar Receives Extension of Nasdaq Listing San Francisco, CA (April 28, 2017): Jaguar Animal Health, Inc. (NASDAQ: JAGX) ( Jaguar ), an animal health company focused on developing and commercializing
Read more →Jaguar and Napo Issue Commercial Updates Jaguar Kicks Off Neonorm Foal TV Campaign & Neonorm Calf Radio Campaign Sales of Neonorm Calf by Jaguar s Distributor ANIMART Up 167% in February 2017 Compared to February 2016 Napo Launches National Sales Force for Mytesi Mytesi Study
Read more →Jaguar Animal Health and Napo Pharmaceuticals Enter Definitive Merger Agreement Merger Will Provide an Important Revenue Stream to Jaguar from Mytesi, an FDA Approved Napo Anti-Diarrheal Launched October 2016 Offering a First-in-Class, Novel Mechanism of Action Highly Conserved
Read more →General Overview February 2017 This presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding Jaguar s intention to merge with Napo, the estimated potential annual sal
Read more →Jaguar Animal Health Enters Binding Agreement of Terms to Merge with Napo Pharmaceuticals Merger Will Provide an Important Revenue Stream to Jaguar from Mytesi , an FDA Approved Anti-Diarrheal Launched October 2016 that Offers a First-in-Class, Novel Mechanism of Action Jaguar
Read more →Jaguar Animal Health, Elanco Enter Global Collaboration for Development, Co-Promotion of Canalevia Agreement provides Elanco with license rights to Jaguar s crofelemer-based drug product candidates for treatment of diarrhea in dogs and other companion animals Jaguar Animal Heal
Read more →Jaguar Animal Health Appoints Dr. Ari Azhir to Board of Directors San Francisco, CA (December 19, 2016): Jaguar Animal Health, Inc. (NASDAQ: JAGX) ( Jaguar ), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companio
Read more →Jaguar Animal Health and Henry Schein, Inc. Sign Exclusive Distribution Agreement for Neonorm Foal San Francisco, CA (December 12, 2016): Jaguar Animal Health, Inc. (NASDAQ: JAGX) ( Jaguar ), an animal health company focused on developing and commercializing first-in-class gastr
Read more →Jaguar Animal Health Announces Private Placement of Common Stock and Warrants San Francisco, CA (November 23, 2016) - Jaguar Animal Health, Inc. (NASDAQ: JAGX) ( Jaguar ), an animal health company focused on developing and commercializing first-in-class gastrointestinal products
Read more →Jaguar Animal Health and Napo Pharmaceuticals Announce Details for Proposed Merger Merger Would Allow Jaguar to Recognize an Important Revenue Stream from First-in-Class, Novel Mechanism of Action of the Anti-diarrheal Mytesi San Francisco, CA (October 6, 2016) - Jaguar Animal
Read more →Jaguar Animal Health Signs Exclusive Distribution Agreement for Croton Lechleri Botanical Extract for Pigs and Dairy Cattle in the Chinese Marketplace San Francisco, CA (September 7, 2016) - Jaguar Animal Health, Inc. (NASDAQ: JAGX) ( Jaguar or the Company ), an animal health co
Read more →Corporate Presentation May 2016 This presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding the anticipated timing of the commercial launch of Canalevia, and the ti
Read more →DEAR FELLOW STOCKHOLDERS, Fiscal year 2015 was a year of important progress for Jaguar Animal Health. Since the completion of our initial public offering in May 2015, we have delivered on multiple clinical, product development and operational milestones. I am both delighted by t
Read more →Jaguar Animal Health Appoints John Micek III to Board of Directors San Francisco, CA (April 6, 2016): Jaguar Animal Health, Inc. (NASDAQ: JAGX) ( Jaguar or the Company ), an animal health company focused on developing and commercializing first-in-class gastrointestinal products
Read more →Jaguar Animal Health Appoints Karen Wright as Chief Financial Officer SAN FRANCISCO (BUSINESS WIRE) Jaguar Animal Health, Inc. (NASDAQ:JAGX) ( Jaguar or the Company ), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for
Read more →Jaguar Animal Health Signs Crofelemer Formulation Development and Manufacturing Contract with Patheon Contract Secured in Preparation for Pivotal Trial & Expected Launch of Jaguar s Prescription Drug Candidate, Canalevia, for Acute Diarrhea in Dogs Jaguar to Leverage Patheon s
Read more →Jaguar Animal Health Signs Crofelemer Manufacturing & Supply Agreement with Glenmark Pharmaceuticals Ltd. San Francisco, CA (September 28, 2015): Jaguar Animal Health, Inc. (NASDAQ: JAGX) ( Jaguar or the Company ), an animal health company focused on developing and commercializi
Read more →